GH Research PLC
GHRS
View Detailed Chart
13.530USD
-0.790-5.52%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
812.33MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.52%
5 Days
-5.48%
1 Month
+3.28%
6 Months
+18.79%
Year to Date
+93.29%
1 Year
+66.01%
View Detailed Chart
TradingKey Stock Score of GH Research PLC
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GH Research PLC's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
31.125
Target Price
+117.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
GH Research PLC Highlights
StrengthsRisks
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -19.43, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.68M shares, decreasing 2.83% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
GH Research PLC Info
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Ticker SymbolGHRS
CompanyGH Research PLC
CEODr. Velichka (Villy) Valcheva, M.D.
Website
Related Instruments
+0.95%
-1.78%
-2.37%
-1.19%
+0.44%
+0.04%
+1.56%
-1.27%
-3.65%
-1.76%
+3.54%
-0.31%
-0.87%
+0.83%
-1.58%
-2.50%
-2.09%
-1.56%
0.00%
-0.67%Popular Symbols
